Ultimate magazine theme for WordPress.

- реклама -

U S Awards Moderna $590 Million to Speed Development of MRNA Avian Influenza Vaccine 2025

0

The U.S. Department of Health and Human Services (HHS) has awarded Moderna $590 million to expedite the development of an mRNA-based H5N1 avian influenza vaccine. This funding supplements a previous $176 million grant from HHS, bringing the total investment to $766 million.
REUTERS

The additional funds will support Moderna in advancing its experimental vaccine, mRNA-1018, into late-stage clinical trials. Preliminary data from early-stage trials have been promising, with more detailed results expected to be presented at an upcoming medical meeting.
REUTERS

This initiative is part of a broader effort by the U.S. government to enhance pandemic preparedness, especially in light of recent human infections and the first avian flu-related death in the United States. The Centers for Disease Control and Prevention (CDC) has upgraded its advisory on H5N1, recommending that all hospitalized flu patients be tested within 24 hours. Despite these developments, the CDC maintains that the risk to the general public remains low, with no evidence of person-to-person transmission.
MARKETWATCH

Moderna’s Chief Financial Officer, Jamey Mock, has reassured that the company retains sufficient capacity to manufacture the vaccine and could scale up production rapidly if a pandemic arises.

Оставьте ответ

Ваш электронный адрес не будет опубликован.